Online citations, reference lists, and bibliographies.
← Back to Search

Prolonged Survival After Talc Poudrage For Malignant Pleural Mesothelioma: Case Series

Y. Aelony, J. Yao
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Objective:  Malignant pleural mesothelioma is a fatal disease with a mean life expectancy of 6–12 months. Since 1982, we have performed thoracoscopic talc poudrage (TTP) as a primary therapy in mesothelioma patients presenting with pleural effusion. As the survival data for our patients surpassed that of many published series, the patient data was analyzed to determine whether talc poudrage can be considered as a contemporary palliative option.
This paper references
Projections of asbestos-related disease
AM Walker (1980)
The Grondin/Sugarbaker article reviewed
VW Rusch (1999)
Survival with malignant pleural mesothelioma after talc poudrage
Y. Aelony (1991)
10.1016/0169-5002(95)00508-0
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
10.1016/S0003-4975(99)01038-3
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
10.1016/S0003-4975(10)64593-6
Extrapleural pneumonectomy for diffuse, malignant mesothelioma.
M. Davalle (1986)
10.1001/JAMA.252.1.86
Pleural mesothelioma and neighborhood asbestos exposure
A. Fischbein (1984)
Thoracoscopic talc pleurodesis (TTP) under local anesthesia
Y Aelony (1998)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1097/00000421-199002000-00002
The Treatment of Malignant Mesothelioma of the Pleura: Review of a 5‐Year Experience, With Special Reference to Radiotherapy
D. Ball (1990)
10.1378/CHEST.116.2.391
Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.
M. Metintas (1999)
Diffuse malignant mesothelioma: a therapeutic
RJ Ginsberg (1986)
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
10.1183/09031936.96.09122565
Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study.
C. J. Lindén (1996)
10.1164/RCCM.200201-006OC
Autonomic modulation of heart rate during obstructive versus central apneas in patients with sleep-disordered breathing.
L. Spicuzza (2003)
Treat - ment of malignant mesothelioma with methotrexate and vinblastine , with or without platinum chemother
KJ Hunt (1996)
10.1164/AJRCCM.161.2.9904123
Talc induces apoptosis in human malignant mesothelioma cells in vitro.
N. Nasreen (2000)
10.1201/B14205-28
Malignant pleural effusions.
S. Sahn (1985)
10.1378/CHEST.117.1.73
Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease.
C. Burrows (2000)
Projections of asbestos-related disease 1980-2009.
A. Walker (1983)
10.1378/CHEST.113.4.1007
Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH.
Y. Aelony (1998)
10.1016/0003-4975(94)91066-9
Aggressive multimodality therapy for malignant pleural mesothelioma.
T. Rice (1994)
10.7326/0003-4819-96-6-746
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
10.1136/thx.39.4.255
Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.
M. Law (1984)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.1016/S0022-5223(19)40189-X
Malignant pleural mesothelioma. Report of 19 cases.
J. Shearin (1976)
10.1136/THX.53.1.21
Expression of growth factors and remodelling of the airway wall in bronchial asthma.
M. Hoshino (1998)
10.1055/S-2007-1013677
Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions.
A. Cantó (1997)
10.1016/0011-3840(93)90029-G
Malignant pleural mesothelioma.
H. Pass (2004)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
Pleural fluid pH as a predictive value for survival in epithelial malignant mesothelioma patients: a significant addition to staging procedures
Y Aelony (2003)
10.1378/CHEST.93.1.159
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
E. Chailleux (1988)
10.1136/thorax.2003.009290
BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112
M. Muers (2004)
10.1378/CHEST.100.4.1003
Pleural fluid analysis in malignant mesothelioma. Prognostic implications.
A. Gottehrer (1991)
10.1016/S0003-4975(10)64591-2
Diffuse Malignant Mesothelisoma: A Therapeutic Dilemma
R. Ginsberg (1986)
10.7326/0003-4819-115-10-778
Thoracoscopic talc poudrage pleurodesis for chronic recurrent pleural effusions.
Y. Aelony (1991)
10.1378/CHEST.109.5.1239
Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy.
K. Hunt (1996)
Diffuse malignant mesothelioma: a therapeutic dilemma.
R. Ginsberg (1986)
Malignant mesothelioma of the pleura.
K. Sirola (1959)
[Chances and results of surgery of malignant mesothelioma of the pleura (author's transl)].
H. Wörn (1974)
10.1378/CHEST.122.6.2256
Cardiac decortication (epicardiectomy) for occult constrictive cardiac physiology after left extrapleural pneumonectomy.
J. Byrne (2002)
10.1378/CHEST.110.6.1387
Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases.
J. Viallat (1996)
Thirty years of mesothelioma in Barrow-in-Furness
RB Gore (1998)
10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
10.1016/0007-0971(83)90068-2
Malignant mesothelioma 1982: review of 4710 published cases.
G. Hillerdal (1983)
10.1016/0002-9343(80)90103-5
Multimodality therapy for malignant mesothelioma based on a study of natural history.
K. H. Antman (1980)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
Talc induces apoptosis in human mesothelioma cells in vitro
N Nasreen (2000)
10.1002/1097-0142(19840201)53:3<377::AID-CNCR2820530302>3.0.CO;2-B
Malignant mesothelioma. The university of minnesota experience
N. Vogelzang (1984)
10.1001/JAMA.1984.03350010052024
Pleural mesothelioma and neighborhood asbestos exposure. Findings from microchemical analysis of lung tissue.
A. Fischbein (1984)
10.1164/AJRCCM/139.3.663
Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis.
F. Rodríguez-Panadero (1989)
Thoracoscopic talc pleurodesis (TTP) under local anesthesia. 10th World Congress for Bronchology and 10th World Congress for Bronchoesophagology
Y. Aelony (1998)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)



This paper is referenced by
10.1097/JTO.0b013e3181e95cb8
Prognostic Factors for Survival after Surgical Palliation of Malignant Pleural Effusion
J. Pilling (2010)
10.5152/ejp.2014.50133
Surgical Procedures Performed in Management of Malignant Pleural Effusions
T. Lacin (2015)
10.1016/S0169-5002(07)70145-9
Pleurodesis in follow-up and treatment of malignant pleural mesothelioma patients.
Güntülü Ak (2009)
Mesothéliome en 2010
Yossef Aelony (2011)
10.1016/J.ATHORACSUR.2006.03.108
Staging in malignant mesothelioma.
Y. Aelony (2006)
10.1007/978-3-319-40618-3_37
Malignant pleural mesothelioma.
D. Ettinger (2012)
Mesothelioma in 2010 Mesothéliome en 2010
Y. Aelony (2011)
10.1016/j.thorsurg.2012.10.001
Surgical management of malignant pleural effusions.
S. Murthy (2013)
Malignant Pleural MesotheliomaPractice Guidelines in Oncology
R. Martins (2012)
10.1016/J.DDMEC.2008.01.001
Advances in pleural disease
P. S. Sriram (2007)
10.1159/000342343
The Impact of Tunneled Pleural Catheters on the Quality of Life of Patients with Malignant Pleural Effusions
Natasha F. Sabur (2012)
Mesothelioma: a review.
F. Mott (2012)
10.5761/ATCS.OA.09.01427
Malignant pleural mesothelioma: clinicopathologic and survival characteristic in a consecutive series of 40 patients.
R. Bagheri (2011)
10.1016/j.ctrv.2015.05.001
The established and future biomarkers of malignant pleural mesothelioma.
V. Panou (2015)
10.1111/j.1743-7563.2007.00116.x
Management of malignant pleural mesothelioma
A. Nowak (2007)
10.1159/000343287
Best Current Therapy for Patients with Malignant Pleural Effusion
Y. Aelony (2012)
10.1163/156855207782514978
Talc pleuradesis : a particulate analysis
S. Brown (2007)
10.1183/09031936.00001507
Who's (still) afraid of talc?
M. Noppen (2007)
10.1016/j.ejim.2007.09.014
Prognostic significance of pleural fluid data in patients with malignant effusion.
S. Bielsa (2008)
10.12699/jfvp.4.13.2013.3
Management of malignant pleural effusion at the beginning of 2014 Prise en charge de l'épanchement pleural malin au début de l'année 2014
Y. Aelony (2013)
10.1007/s13665-013-0044-2
Management options for the complicated pleural space
D. Hsia (2013)
10.1378/chest.12-1085
Point: Should thoracoscopic talc pleurodesis be the first choice management for malignant effusion? Yes.
P. Lee (2012)
Table: Comparison of patients' characteristics between pneumonia studies in HIV-endemic areas
Lisa M. McNally (2007)
10.1510/icvts.2010.254789
What is the best treatment for malignant pleural effusions?
I. Zahid (2011)
10.29245/2689-999x/2017/1.1110
Mesothelioma from household asbestos exposure
Flavia D'Agostin (2018)
10.1200/JCO.2006.08.0267
Raltitrexed and pemetrexed studies in mesothelioma have not shown improved quality of life nor prolonged survival compared with effective pleurodesis with thoracoscopic talc poudrage.
Y. Aelony (2006)
10.11648/j.ijcts.20170306.14
Malignant Pleural Mesothelioma: An Update on the Role of Surgery
Maria Kalliopi Konstantinidou (2017)
10.1378/CHEST.12-1086
Rebuttal From Dr Lee
P. Lee (2012)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1097/CPM.0000000000000084
Surgical Perspectives on Management of Malignant Pleural Effusions
Sudish C. Murthy (2015)
10.1183/09031936.00061606
Talc mediates angiostasis in malignant pleural effusions via endostatin induction
N. Najmunnisa (2007)
10.1016/S0140-6736(07)61190-8
Tunnelled pleural catheters in malignant pleural effusion – Author's reply
Y. Aelony (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar